Literature DB >> 10467625

Drug selection and the management of corticosteroid-related diabetes mellitus.

B Hoogwerf1, R D Danese.   

Abstract

Glucocorticoid use is associated with the risk of hyperglycemia in patients without known diabetes mellitus and worsened glycemic control in diabetic patients. The effects are greater in the fed than fasting state. Management includes use of diet and exercise (as appropriate for the individual) in all patients. Mild hyperglycemia can often be managed with oral agents, especially those with rapid onset of action. Marked hyperglycemia, especially in diabetic patients or patients with liver or renal disease, requires insulin. Adjustments in insulin can be done both in anticipation of the glucocorticoid effect and based on home glucose monitoring. The effects of glucocorticoids on hyperglycemia usually remit within 48 hours of discontinuation of oral administration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10467625     DOI: 10.1016/s0889-857x(05)70083-1

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  13 in total

1.  Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease.

Authors:  Seo Yun Kim; Chul-Gyu Yoo; Chun Taeg Lee; Hee Soon Chung; Young Whan Kim; Sung Koo Han; Young-Soo Shim; Jae-Joon Yim
Journal:  J Korean Med Sci       Date:  2011-01-24       Impact factor: 2.153

Review 2.  Glycemic control and organ transplantation.

Authors:  Michael R Marvin; Vicki Morton
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

3.  Glucocorticoids differentially regulate the expression of CRFR1 and CRFR2α in MIN6 insulinoma cells and rodent islets.

Authors:  M O Huising; A P Pilbrow; M Matsumoto; T van der Meulen; H Park; J M Vaughan; S Lee; W W Vale
Journal:  Endocrinology       Date:  2010-11-24       Impact factor: 4.736

4.  A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.

Authors:  Subarna M Dhital; Yoram Shenker; Melissa Meredith; Dawn Belt Davis
Journal:  Endocr Pract       Date:  2012 Sep-Oct       Impact factor: 3.443

5.  Glucocorticoid-induced suppression of β-cell proliferation is mediated by Mig6.

Authors:  E Scott Colvin; Hong-Yun Ma; Yi-Chun Chen; Angelina M Hernandez; Patrick T Fueger
Journal:  Endocrinology       Date:  2013-02-05       Impact factor: 4.736

Review 6.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

7.  Increased pancreatic islet mass is accompanied by activation of the insulin receptor substrate-2/serine-threonine kinase pathway and augmented cyclin D2 protein levels in insulin-resistant rats.

Authors:  Alex Rafacho; Daniele Lisboa Ribeiro; Antonio Carlos Boschero; Sebastião Roberto Taboga; José Roberto Bosqueiro
Journal:  Int J Exp Pathol       Date:  2008-04-21       Impact factor: 1.925

8.  Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline.

Authors:  X Kostaras; F Cusano; G A Kline; W Roa; J Easaw
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

9.  Exenatide improves glucocorticoid-induced glucose intolerance in mice.

Authors:  Ruiying Zhao; Enrique Fuentes-Mattei; Guermarie Velazquez-Torres; Chun-Hui Su; Jian Chen; Mong-Hong Lee; Sai-Ching Jim Yeung
Journal:  Diabetes Metab Syndr Obes       Date:  2011-01-26       Impact factor: 3.168

10.  Steroid-induced diabetes: is it just unmasking of type 2 diabetes?

Authors:  Lisa R Simmons; Lynda Molyneaux; Dennis K Yue; Elizabeth L Chua
Journal:  ISRN Endocrinol       Date:  2012-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.